News

CLINUVEL
Posted by CLINUVEL
October 11, 2016

Media release: FDA, CLINUVEL TO DISCUSS SCENESSE® AT PRE-NDA MEETING

11 October 2016 CLINUVEL PHARMACEUTICALS LTD today announced that it will meet...

Read More
CLINUVEL
Posted by CLINUVEL
October 9, 2016

CLINUVEL Confirms Date of Annual General Meeting

09 October 2016 In accordance with ASX listing rules 3.13.1 and 14.3,...

Read More
CLINUVEL
Posted by CLINUVEL
September 19, 2016

Chair's Letter

19 September 2016 This summer our team supplied the first SCENESSE® (afamelanotide...

Read More
CLINUVEL
Posted by CLINUVEL
August 24, 2016

Appendix 4E - Preliminary Final Report 2015/16

24 August 2016 Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...

Read More
CLINUVEL
Posted by CLINUVEL
August 22, 2016

Lapse and Forfeit of Unlisted Conditional Performance Rights

23 August 2016 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...

Read More
CLINUVEL
Posted by CLINUVEL
August 14, 2016

CLINUVEL Newsletter - August 2016

16 August 2016 In the arduous journey from explorative concept to development...

Read More
CLINUVEL
Posted by CLINUVEL
August 9, 2016

Notice of Initial Substantial Holder

10 August 2016 Enclosed are the details of a notice of initial...

Read More
CLINUVEL
Posted by CLINUVEL
August 3, 2016

Appendix 3Y

03 August 2016 We (the entity) give ASX the following information under...

Read More
CLINUVEL
Posted by CLINUVEL
August 2, 2016

Appendix 3B

02 August 2016 New issue announcement, application for quotation of additional securities...

Read More
CLINUVEL
Posted by CLINUVEL
August 2, 2016

CLINUVEL completes pre-clinical study of SCENESSE® as combination therapy

02 August 2016 CLINUVEL prepares New Drug Application (NDA) for the treatment...

Read More